ASCRS

John Berdahl, MD, discusses the technique and benefit of endothelial cell therapy. An early technology, this therapy method allows for up to 100 treatments out of a single human cornea.

Chuck Hess, vice president and general manager, Bausch and Lomb, discusses XIPERE™, the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, and other new things rolled out recently from the company.

Tom Frinzi, executive chairman of ViaLase, a new company based in Orange County, gives an update on the company, sharing some exciting new things happening.

In a presentation at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting, Marjan Farid, MD, ABO, and Preeya K. Gupta, MD, offered details of clinical trials for CSF-1 ophthalmic solution, a presbyopia eye drop candidate. Results showed that nearly half of the participants treated with CSF-1 achieved a 3-line or more increase in the distance-corrected near visual acuity an hour after drop instillation on day 15.

Anushka M. Raj, BS, second year medical student at the University of Oklahoma’s Dean McGee Eye Institute, presents "Inter-Device Measurement Reliability of Angle Kappa and Angle Alpha, Devices and Instruments" during ASCRS.

According to an e-poster presented by Jagadesh C. Reddy, MD, and Harini Indusekar, BScOptom, at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., patients who have pre-existing DR are less likely to achieve Snellen 20/40 or better vison after cataract surgery compared with the patients with diabetes but without DR.

Philip Dockery, MD, MPH, discusses his paper "Corneal cross linking for progressive keratoconus, a retrospective analysis of 515 consecutive eyes," with Ophthalmology Times' David Hutton.

Richard L. Lindstrom, MD, of Minnesota Eye Consultants, discusses his ASCRS presentation, "Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy," with Ophthalmology Times' Sheryl Stevenson.

Blake K. Williamson, MD, MPH, MS, and coauthor Urvi Patel, BSc, presented an e-poster at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., on the efficacy of a combination eye drop comprised of an antibiotic, anti-inflammatory and lubricant as part of a postoperative treatment regimen following cataract surgery.

For the first time, Orasis Pharmaceutical's phase 2b data for the company's novel candidate for the treatment of presbyopia, CSF-1, a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle, will be presented during ASCRS by Marjan Farid, MD, and Preeya Gupta, MD. The company recently released its phase 3 topline results. Orasis' Paul Smith, president and COO, talks with Ophthalmology Times' Sheryl Stevenson about this data and the findings' relevance to patients and providers.

In an e-poster presented at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., Abdelrahman M. Elhusseiny, MD, MSc, noted a research team found that cenegermin was effective for improving the corneal healing in these pediatric patients.

Christina Weng, associate professor of ophthalmology, Baylor College of Medicine, Houston, talked about the importance of managing potential pseudophakic cystoid macular edema (CME) following cataract surgery.

Shervin Korangy, CEO of BVI, shares about the company's new technology, Beyeonics One, on display during ASCRS 2022.

About 65% of patients sought follow-up care for glaucoma after presentation to the Wills Eye Hospital emergency room (ER), according to Elliot G. Cherkas, BSc, the lead author of the study.

Ophthalmologists and industry executives share what lingers on their minds at the end of the day.

Robert Weinstock, MD, discusses the efficacy and safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for eyes receiving cataract surgery.

Cathleen McCabe, MD, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Tibor Juhasz, CEO of ViaLase, Inc, discusses the company's development of a novel, noninvasive high-resolution OCT image-guided femtosecond laser technology for the treatment of open-angle glaucoma.

CXL is safe, effective to perform on younger population, study results show.

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.

Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.

Michael Rivers, MD, discusses how Modernizing Medicine's latest updates to its electronic health records EMA® system benefits both ophthalmologists and optometrists.

Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

Edward Manche, MD, discusses results from his presentation regarding outcomes of corneal crosslinking keratoconus in a pediatric population.

Ed Hu, MD, PhD, shares highlights from his paper analyzing three years' worth of his own postop data on comparative lens rotations in toric IOL platforms.

Mitch Shultz, MD, speaks on the capabilities of a cloud-based database system to look at energy-fluid metrics, provide surgeons with the capacity to refine procedures and give patients better outcomes.

Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.